Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Threonine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 3/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Threonine SCHEMBL1887229 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL7041491 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL28236094 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL28397150 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL27803017 | 1.00 | NOS2 (0.38) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL25330687 | 0.97 | NOS2 (0.36) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL6684384 | 0.97 | NOS2 (0.36) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL28136712 | 0.95 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL28137403 | 0.95 | NOS2 (0.35) | NOS2NOS3NOS1MEN1KMT2A | |
| Threonine SCHEMBL11969543 | 0.93 | NOS2 (0.33) | NOS2NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2196202-B1 | Lys-Pro-Thr and Lys-Pro as inflammation-inhibiting compounds | LUGER THOMAS (DE) | 2013-07-17 | — | — | EP | claimed |
| EP-0537171-A4 | CD46 VARIANTS | — | 1993-06-30 | — | — | EP | claimed |
| EP-0537171-A1 | CD46 VARIANTS | THE AUSTIN RESEARCH INSTITUTE (AU) | 1993-04-21 | — | — | EP | claimed |
| WO-1991018097-A1 | CD46 VARIANTS | UNIVERSITY OF MELBOURNE (AU) | 1991-11-28 | — | — | WO | claimed |
| US-20240207407-A1 | EGFRVIII BINDING PROTEINS | Myrio Therapeutics Pty Ltd (AU) | 2024-06-27 | — | — | US | disclosed |
| WO-2024124286-A1 | THERAPEUTIC EXTRACELLULAR VESICLES | THE UNIVERSITY OF NEWCASTLE (AU) | 2024-06-20 | — | — | WO | disclosed |
| EP-3793586-B1 | SOLUBLE COMPLEMENT RECEPTOR TYPE 1 VARIANTS AND USES THEREOF | CSL LTD (AU) | 2024-04-10 | — | — | EP | disclosed |
| EP-4330285-A1 | EGFRVIII BINDING PROTEINS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2024-03-06 | — | — | EP | disclosed |
| WO-2024038407-A1 | LIPID NANOPARTICLE COMPRISING A DNA-BINDING PROTEIN | Seqirus Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| US-20230399376-A1 | BINDING PROTEINS COMPRISING THE EXTRACELLULAR DOMAIN OF CD39 AND METHODS OF TREATING OR PREVENTING NEUROLOGICAL DISEASES | BAKER HEART AND DIABETES INST (AU) | 2023-12-14 | — | — | US | disclosed |
| WO-2022226584-A1 | EGFRvIII BINDING PROTEINS | THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH (AU) | 2022-11-03 | — | — | WO | disclosed |
| US-20220305133-A1 | Soluble Complement Receptor Type 1 Variant Conjugates and Uses Thereof | CSL Innovation Pty., Ltd. (AU) | 2022-09-29 | — | — | US | disclosed |
| WO-2002079418-A2 | GENE REGULATION II | GENDAQ LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| WO-2002074996-A1 | GENE REGULATION | GENDAQ LIMITED (GB) | 2002-09-26 | — | — | WO | disclosed |
| WO-2002057308-A2 | ZINC FINGER POLYPEPTIDES AND THEIR USE | SANGAMO BIOSCIENCES, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| WO-2002004488-A2 | NUCLEIC ACID BINDING POLYPEPTIDES | SANGAMO BIOSCIENCES, INC. (US) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001085780-A2 | NUCLEIC ACID BINDING POLYPEPTIDES | GENDAQ LIMITED (GB) | 2001-11-15 | — | — | WO | disclosed |
| US-6303357-B1 | HEAT STABLE ENZYMATIC POLYPEPTIDE; FOR USE AS A DIAGNOSTIC TOOL IN MEASUREMENT OF LIPASE ACTIVITY AND DETERMINATION OF TRIGLYCERIDE, GLYCEROL, ADENOSINE TRIPHOSPHATE CONCENTRATIONS | AMANO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| EP-1138769-A1 | Recombinant L-alpha-glycerophosphate oxidase gene, and method for producing the same | AMANO PHARMACEUTICAL CO., LTD. (JP) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001053480-A1 | NUCLEIC ACID BINDING POLYPEPTIDES CHARACTERIZED BY FLEXIBLE LINKERS CONNECTED NUCLEIC ACID BINDING MODULES | SANGAMO BIOSCIENCES, INC. (US) | 2001-07-26 | — | — | WO | disclosed |